<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00239642</url>
  </required_header>
  <id_info>
    <org_study_id>1VEN03017</org_study_id>
    <nct_id>NCT00239642</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Iron Sucrose in Children</brief_title>
  <official_title>Comparison of the Safety and Efficacy of Three Iron Sucrose Maintenance Regimens in Pediatric Chronic Kidney Disease (CKD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luitpold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luitpold Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      Comparison of three potential iron sucrose maintenance regimens in pediatric chronic kidney
      disease (CKD) patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, controlled, open label trial of pediatric CKD patients on stable erythropoietin
      (EPO) therapy. Patients will be followed for 12 weeks to assess safety (incidence of adverse
      events) and efficacy (clinical success)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Profile: Number of Subjects Experiencing at Least 1 Adverse Event</measure>
    <time_frame>baseline through week 12</time_frame>
    <description>Safety Profile: Number of subjects who experienced at least 1 adverse event in each arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Clinical Success</measure>
    <time_frame>anytime during the 12 week post-baseline period</time_frame>
    <description>Summary of the Number of Subjects Achieving Clinical Success During the 12-Week Study Period - Hemoglobin between 10.5 g/dL and 14.0 g/dL, Inclusive, TSAT between 20% and 50%, Inclusive, and Stable EPO Dosing (±25% of Baseline Dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of Subjects Achieving Clinical Success</measure>
    <time_frame>anytime during the 12 week post-baseline period</time_frame>
    <description>Summary of the Percentage (%) of Subjects Achieving Clinical Success During the 12-Week Study Period - Hemoglobin between 10.5 g/dL and 14.0 g/dL, Inclusive, TSAT between 20% and 50%, Inclusive, and stable EPO Dosing (±25% of Baseline Dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Hemoglobin Between 10.5 g/dL and 14.0 g/dL, Inclusive</measure>
    <time_frame>anytime during the 12-week post-baseline period</time_frame>
    <description>Summary of the Number of Subjects with Hemoglobin between 10.5 g/dL and 14.0 g/dL, Inclusive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of Subjects With Hemoglobin Between 10.5 g/dL and 14.0 g/dL, Inclusive</measure>
    <time_frame>anytime during the 12 week post-baseline period</time_frame>
    <description>Summary of the Percentage (%) of Subjects with Hemoglobin Between 10.5 g/dL and 14.0 g/dL, Inclusive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With Transferrin Saturation (TSAT) Between 20% and 50%, Inclusive</measure>
    <time_frame>anytime during the 12 week post-baseline period</time_frame>
    <description>Summary of the Proportion of Subjects with transferrin saturation (TSAT) between 20% and 50%, Inclusive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of Subjects With TSAT Between 20% and 50%, Inclusive</measure>
    <time_frame>anytime during the 12 week post-baseline period</time_frame>
    <description>Summary of the Percentage (%) of Subjects with TSAT between 20% and 50%, Inclusive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With Stable Erythropoietin (EPO) Dosing or a Decrease &gt;25% in EPO Dose From Baseline</measure>
    <time_frame>anytime during the 12 week post-baseline period</time_frame>
    <description>Summary of the Proportion of Subjects with Stable erythropoietin (EPO) Dosing or a Decrease &gt;25% in EPO dose from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of Subjects With Stable EPO Dosing or a Decrease &gt;25% in EPO Dose From Baseline</measure>
    <time_frame>anytime during the 12 week post-baseline period</time_frame>
    <description>Summary of the Percentage (%) of Subjects with Stable EPO Dosing or a Decrease &gt;25% in EPO Dose from Baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Anemia</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Venofer (0.5 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venofer (1.0 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venofer (2.0 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venofer (iron sucrose injection)</intervention_name>
    <description>0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
    <arm_group_label>Venofer (0.5 mg/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venofer (iron sucrose injection)</intervention_name>
    <description>1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
    <arm_group_label>Venofer (1.0 mg/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venofer (iron sucrose injection)</intervention_name>
    <description>2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
    <arm_group_label>Venofer (2.0 mg/kg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 2 to 21 years of age

          -  Patients on stable hemodialysis (HD) or peritoneal dialysis (PD) regimen for 3 months
             for ≥ 3 months

          -  Non-dialysis dependent (NDD) patients with glomerular filtration rate (GFR) &lt;60

          -  Hemoglobin (Hgb) ≥ 11g/dL to ≤ 13.5g/dL

          -  Ferritin ≤ 800 ng/mL

          -  Transferrin saturation (TSAT) ≥ 20% to ≤ 50%

          -  Received stable erythropoietin (EPO) regimen for ≥ 8 weeks prior to the qualifying
             screening visit

        Exclusion Criteria:

          -  Known hypersensitivity to iron sucrose

          -  Severe diseased of the liver, cardiovascular system, or hemopoietic system

          -  Serious infection requiring hospitalization

          -  Significant blood loss within the last 3 months

          -  Bleeding disorders

          -  Pregnancy / Lactation

          -  Actively being treated for asthma

          -  Hemoglobinopathy

          -  Receiving a myelosuppressive drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A Falone, MD</last_name>
    <role>Study Director</role>
    <affiliation>Luitpold Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Luitpold Pharmaceutials</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2005</study_first_submitted>
  <study_first_submitted_qc>October 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2005</study_first_posted>
  <results_first_submitted>December 5, 2011</results_first_submitted>
  <results_first_submitted_qc>December 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 10, 2012</results_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iron</keyword>
  <keyword>Anemia</keyword>
  <keyword>CKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric oxide, saccharated</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Hospitals and Medical Clinics; Study Period - October 24, 2005 through January 23, 2009</recruitment_details>
      <pre_assignment_details>Stable erythropoietin (EPO) dose (±25% of current dose) for 8 weeks prior to the qualifying screening visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Venofer (0.5 mg/kg)</title>
          <description>0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
        </group>
        <group group_id="P2">
          <title>Venofer (1.0 mg/kg)</title>
          <description>1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
        </group>
        <group group_id="P3">
          <title>Venofer (2.0 mg/kg)</title>
          <description>2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Venofer (0.5 mg/kg)</title>
          <description>0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
        </group>
        <group group_id="B2">
          <title>Venofer (1.0 mg/kg)</title>
          <description>1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
        </group>
        <group group_id="B3">
          <title>Venofer (2.0 mg/kg)</title>
          <description>2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="145"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.8" spread="4.40"/>
                    <measurement group_id="B2" value="13.1" spread="4.62"/>
                    <measurement group_id="B3" value="13.1" spread="4.87"/>
                    <measurement group_id="B4" value="13.3" spread="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety Profile: Number of Subjects Experiencing at Least 1 Adverse Event</title>
        <description>Safety Profile: Number of subjects who experienced at least 1 adverse event in each arm</description>
        <time_frame>baseline through week 12</time_frame>
        <population>Safety Population - Subjects who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Venofer (0.5 mg/kg)</title>
            <description>0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Venofer (1.0 mg/kg)</title>
            <description>1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Venofer (2.0 mg/kg)</title>
            <description>2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Profile: Number of Subjects Experiencing at Least 1 Adverse Event</title>
          <description>Safety Profile: Number of subjects who experienced at least 1 adverse event in each arm</description>
          <population>Safety Population - Subjects who received at least 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Clinical Success</title>
        <description>Summary of the Number of Subjects Achieving Clinical Success During the 12-Week Study Period - Hemoglobin between 10.5 g/dL and 14.0 g/dL, Inclusive, TSAT between 20% and 50%, Inclusive, and Stable EPO Dosing (±25% of Baseline Dose)</description>
        <time_frame>anytime during the 12 week post-baseline period</time_frame>
        <population>mITT subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Venofer (0.5 mg/kg)</title>
            <description>0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Venofer (1.0 mg/kg)</title>
            <description>1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Venofer (2.0 mg/kg)</title>
            <description>2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Clinical Success</title>
          <description>Summary of the Number of Subjects Achieving Clinical Success During the 12-Week Study Period - Hemoglobin between 10.5 g/dL and 14.0 g/dL, Inclusive, TSAT between 20% and 50%, Inclusive, and Stable EPO Dosing (±25% of Baseline Dose)</description>
          <population>mITT subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage (%) of Subjects Achieving Clinical Success</title>
        <description>Summary of the Percentage (%) of Subjects Achieving Clinical Success During the 12-Week Study Period - Hemoglobin between 10.5 g/dL and 14.0 g/dL, Inclusive, TSAT between 20% and 50%, Inclusive, and stable EPO Dosing (±25% of Baseline Dose)</description>
        <time_frame>anytime during the 12 week post-baseline period</time_frame>
        <population>mITT subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Venofer (0.5 mg/kg)</title>
            <description>0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Venofer (1.0 mg/kg)</title>
            <description>1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Venofer (2.0 mg/kg)</title>
            <description>2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage (%) of Subjects Achieving Clinical Success</title>
          <description>Summary of the Percentage (%) of Subjects Achieving Clinical Success During the 12-Week Study Period - Hemoglobin between 10.5 g/dL and 14.0 g/dL, Inclusive, TSAT between 20% and 50%, Inclusive, and stable EPO Dosing (±25% of Baseline Dose)</description>
          <population>mITT subjects</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7"/>
                    <measurement group_id="O2" value="88.9"/>
                    <measurement group_id="O3" value="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Hemoglobin Between 10.5 g/dL and 14.0 g/dL, Inclusive</title>
        <description>Summary of the Number of Subjects with Hemoglobin between 10.5 g/dL and 14.0 g/dL, Inclusive</description>
        <time_frame>anytime during the 12-week post-baseline period</time_frame>
        <population>mITT subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Venofer (0.5 mg/kg)</title>
            <description>0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Venofer (1.0 mg/kg)</title>
            <description>1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Venofer (2.0 mg/kg)</title>
            <description>2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Hemoglobin Between 10.5 g/dL and 14.0 g/dL, Inclusive</title>
          <description>Summary of the Number of Subjects with Hemoglobin between 10.5 g/dL and 14.0 g/dL, Inclusive</description>
          <population>mITT subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage (%) of Subjects With Hemoglobin Between 10.5 g/dL and 14.0 g/dL, Inclusive</title>
        <description>Summary of the Percentage (%) of Subjects with Hemoglobin Between 10.5 g/dL and 14.0 g/dL, Inclusive</description>
        <time_frame>anytime during the 12 week post-baseline period</time_frame>
        <population>mITT subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Venofer (0.5 mg/kg)</title>
            <description>0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Venofer (1.0 mg/kg)</title>
            <description>1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Venofer (2.0 mg/kg)</title>
            <description>2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage (%) of Subjects With Hemoglobin Between 10.5 g/dL and 14.0 g/dL, Inclusive</title>
          <description>Summary of the Percentage (%) of Subjects with Hemoglobin Between 10.5 g/dL and 14.0 g/dL, Inclusive</description>
          <population>mITT subjects</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="95.6"/>
                    <measurement group_id="O3" value="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With Transferrin Saturation (TSAT) Between 20% and 50%, Inclusive</title>
        <description>Summary of the Proportion of Subjects with transferrin saturation (TSAT) between 20% and 50%, Inclusive</description>
        <time_frame>anytime during the 12 week post-baseline period</time_frame>
        <population>mITT subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Venofer (0.5 mg/kg)</title>
            <description>0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Venofer (1.0 mg/kg)</title>
            <description>1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Venofer (2.0 mg/kg)</title>
            <description>2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Transferrin Saturation (TSAT) Between 20% and 50%, Inclusive</title>
          <description>Summary of the Proportion of Subjects with transferrin saturation (TSAT) between 20% and 50%, Inclusive</description>
          <population>mITT subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage (%) of Subjects With TSAT Between 20% and 50%, Inclusive</title>
        <description>Summary of the Percentage (%) of Subjects with TSAT between 20% and 50%, Inclusive</description>
        <time_frame>anytime during the 12 week post-baseline period</time_frame>
        <population>mITT subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Venofer (0.5 mg/kg)</title>
            <description>0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Venofer (1.0 mg/kg)</title>
            <description>1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Venofer (2.0 mg/kg)</title>
            <description>2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage (%) of Subjects With TSAT Between 20% and 50%, Inclusive</title>
          <description>Summary of the Percentage (%) of Subjects with TSAT between 20% and 50%, Inclusive</description>
          <population>mITT subjects</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7"/>
                    <measurement group_id="O2" value="93.3"/>
                    <measurement group_id="O3" value="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With Stable Erythropoietin (EPO) Dosing or a Decrease &gt;25% in EPO Dose From Baseline</title>
        <description>Summary of the Proportion of Subjects with Stable erythropoietin (EPO) Dosing or a Decrease &gt;25% in EPO dose from Baseline</description>
        <time_frame>anytime during the 12 week post-baseline period</time_frame>
        <population>mITT subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Venofer (0.5 mg/kg)</title>
            <description>0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Venofer (1.0 mg/kg)</title>
            <description>1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Venofer (2.0 mg/kg)</title>
            <description>2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Stable Erythropoietin (EPO) Dosing or a Decrease &gt;25% in EPO Dose From Baseline</title>
          <description>Summary of the Proportion of Subjects with Stable erythropoietin (EPO) Dosing or a Decrease &gt;25% in EPO dose from Baseline</description>
          <population>mITT subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage (%) of Subjects With Stable EPO Dosing or a Decrease &gt;25% in EPO Dose From Baseline</title>
        <description>Summary of the Percentage (%) of Subjects with Stable EPO Dosing or a Decrease &gt;25% in EPO Dose from Baseline</description>
        <time_frame>anytime during the 12 week post-baseline period</time_frame>
        <population>mITT subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Venofer (0.5 mg/kg)</title>
            <description>0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Venofer (1.0 mg/kg)</title>
            <description>1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Venofer (2.0 mg/kg)</title>
            <description>2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage (%) of Subjects With Stable EPO Dosing or a Decrease &gt;25% in EPO Dose From Baseline</title>
          <description>Summary of the Percentage (%) of Subjects with Stable EPO Dosing or a Decrease &gt;25% in EPO Dose from Baseline</description>
          <population>mITT subjects</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years and 10 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Venofer (0.5 mg/kg)</title>
          <description>0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
        </group>
        <group group_id="E2">
          <title>Venofer (1.0 mg/kg)</title>
          <description>1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
        </group>
        <group group_id="E3">
          <title>Venofer (2.0 mg/kg)</title>
          <description>2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Enterobacter bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Renal Transplant</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Renal Transplant</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark A. Falone, MD</name_or_title>
      <organization>Luitpold Pharmaceuticals, Inc.</organization>
      <phone>601-650-4200</phone>
      <email>mfalone@luitpold.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

